Base Therapeutics' NK Cell Therapy for Solid Tumors Receives FDA IND Approval
Key Insights
Base Therapeutics (search)' NK510 program, an NK cell therapy for advanced solid tumors (search), has received FDA IND approval, marking a significant milestone.
The therapy utilizes GenScript (search)'s cGMP sgRNA for base editing and CytoSinct™ platform for cell isolation, showcasing a collaborative approach.
NK510 leverages AccuBase (search)® technology for precise gene modification in NK cells, achieving over 90% editing efficiency in preclinical studies.
Base Therapeutics (search) has received FDA Investigational New Drug (IND) approval for its NK510 program, a novel NK cell therapy designed for the treatment of advanced solid tumors (search). The NK510 program utilizes GenScript (search)'s cGMP sgRNA for base editing, along with the CytoSinct™ Cell Isolation Nanobeads (GMP) and CytoSinct™ 1000 instruments for cell isolation.
This marks the first FDA IND approval of a base-edited NK cell program, building on the momentum from NK510's clinical trial approval by China's NMPA in October 2024. The therapy represents a significant advancement in the field of cancer immunotherapy, offering a potential "off-the-shelf" allogeneic NK cell solution.
AccuBase® Technology
NK510 leverages AccuBase (search)®, Base Therapeutics (search)' proprietary zero off-target base editor with global freedom to operate (FTO) protection. This technology enables precise modification of key genes in NK cells, achieving over 90% editing efficiency. According to Dr. Tianhong Xu, founder of Base Therapeutics, this achievement "marks a significant breakthrough in base editing technology" and underscores the company's commitment to innovation, safety, and efficacy.
GenScript's Role
GenScript (search) Biotech played a crucial role in the development of NK510, serving as the sole provider of RUO to cGMP sgRNA material and the cell isolation platform. Dr. Ray Chen, President of the Life Science Group at GenScript, stated that this collaboration "underscores GenScript's capabilities in supporting gene and cell therapy clients in achieving global IND approvals in an expedited timeline, ultimately helping them make innovative therapies more accessible worldwide."
GMP Guide RNA and Cell Isolation
GenScript (search)'s expertise in nucleic acid synthesis is highlighted by its ability to produce cGMP gRNA up to 140 nucleotides long at gram-scale quantities. This capability supports a wide range of editing technologies, including Cas9, Cas12a, base editing, and prime editing. Furthermore, GenScript's CytoSinct™ platform, utilizing advanced nanoparticle-empowered immuno-magnetic isolation technology, ensures high precision and reliability in cell isolation.
About Base Therapeutics
Founded in 2021, Base Therapeutics (search) is focused on gene editing and cell-based therapies for cancer and genetic diseases. The company operates with 2,500 square meters of GMP-compliant manufacturing space and 1,500 square meters of lab facilities, adhering to rigorous production standards required by both US and Chinese regulatory bodies.